← All trials
NCT04311294
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Mar 17, 2020
- Last posted
- Mar 18, 2020
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, Los AngelesLead sponsor
- Amygdala Neurosciences, Inc.Collaborator
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator
- University of California, Los AngelesOfficial
- University of California, Los AngelesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.